ATE534401T1 - Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe - Google Patents

Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe

Info

Publication number: ATE534401T1
Authority: AT; Austria
Prior art keywords: protein; fragment; vaccines containing; antigen coupled; mage antigen
Prior art date: 2000-10-18

Application number

AT07121675T

Other languages

English (en)

Inventor

Nathalie Garcon

Catherine Marie Gerard

Jean Stephenne

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2001-10-16

Publication date

2011-12-15

2000-10-18 Priority claimed from US09/690,921 external-priority patent/US6544518B1/en

2000-10-18 Priority claimed from GB0025573A external-priority patent/GB0025573D0/en

2000-10-18 Priority claimed from GB0025574A external-priority patent/GB0025574D0/en

2001-10-16 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE534401T1 publication Critical patent/ATE534401T1/de

Links

239000000427 antigen Substances 0.000 title abstract 3
102000036639 antigens Human genes 0.000 title abstract 3
108091007433 antigens Proteins 0.000 title abstract 3
238000012737 microarray-based gene expression Methods 0.000 title abstract 2
238000012243 multiplex automated genomic engineering Methods 0.000 title abstract 2
239000012634 fragment Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
239000002671 adjuvant Substances 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
229940035032 monophosphoryl lipid a Drugs 0.000 abstract 2
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
101710188053 Protein D Proteins 0.000 abstract 1
101710132893 Resolvase Proteins 0.000 abstract 1
239000002158 endotoxin Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
229920006008 lipopolysaccharide Polymers 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
229930182490 saponin Natural products 0.000 abstract 1
150000007949 saponins Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
Peptides Or Proteins (AREA)
Permanent Magnet Type Synchronous Machine (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT07121675T 2000-10-18 2001-10-16 Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe ATE534401T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/690,921 US6544518B1 (en)	1999-04-19	2000-10-18	Vaccines
GB0025573A GB0025573D0 (en)	2000-10-18	2000-10-18	Vaccine
GB0025574A GB0025574D0 (en)	2000-10-18	2000-10-18	Vaccine

Publications (1)

Publication Number	Publication Date
ATE534401T1 true ATE534401T1 (de)	2011-12-15

Family

ID=34082077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07121675T ATE534401T1 (de)	2000-10-18	2001-10-16	Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe

Country Status (13)

Country	Link
US (1)	US20050019340A1 (de)
EP (1)	EP2266603B1 (de)
JP (1)	JP2008285487A (de)
KR (1)	KR100831139B1 (de)
AT (1)	ATE534401T1 (de)
CY (3)	CY1108526T1 (de)
DE (1)	DE60131670T2 (de)
DK (2)	DK1889630T3 (de)
ES (2)	ES2392943T3 (de)
IL (1)	IL155282A (de)
PL (1)	PL211151B1 (de)
PT (3)	PT1326638E (de)
SI (1)	SI2266603T1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7956043B2 (en) *	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1608403A2 (de) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
ES2395818T3 (es) *	2004-07-13	2013-02-15	Charite - Universitatsmedizin Berlin	Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
CN116650634A (zh) *	2022-02-18	2023-08-29	天津科技大学	一种免疫佐剂和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3238190A (en)	1963-10-23	1966-03-01	Madaus & Co K G Fa Dr	Aescin recovery
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
SE8205892D0 (sv)	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4806350A (en) *	1986-04-18	1989-02-21	Norden Laboratories, Inc.	Vaccine formulation
US6222020B1 (en)	1987-01-07	2001-04-24	Imperial Cancer Research Technology Limited	Antigens derived from the core protein of the human mammary epithelial mucin
CA1339204C (en)	1987-01-07	1997-08-05	Joyce Taylor-Papadimitriou	Mucin core polypeptide, antibodies and probes
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US4963484A (en)	1988-01-29	1990-10-16	Dana-Farber Cancer Institute, Inc.	Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
WO1990014837A1 (en)	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr)	1989-07-03	1991-10-25	Seppic Sa	Emulsions multiphasiques injectables
FR2649013B1 (fr)	1989-07-03	1991-10-25	Seppic Sa	Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5256643A (en)	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja)	1991-12-23	2005-12-07	ディミナコアクチェンゲゼルシャフト	アジュバント
DE69313134T2 (de)	1992-06-25	1998-02-26	Smithkline Beecham Biolog	Adjuvantien enthaltende impfstoffzusammensetzung
US5786148A (en)	1996-11-05	1998-07-28	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding a novel prostate-specific kallikrein
US5801005A (en)	1993-03-17	1998-09-01	University Of Washington	Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
KR100310510B1 (ko)	1993-03-23	2002-07-04	장 스테판느	3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5744144A (en)	1993-07-30	1998-04-28	University Of Pittsburgh University Patent Committee Policy And Procedures	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
PT729473E (pt)	1993-11-17	2001-02-28	Deutsche Om Arzneimittel Gmbh	Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5688506A (en)	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en)	1996-10-05	1996-11-20	Smithkline Beecham Plc	Vaccines
US5668267A (en)	1995-05-31	1997-09-16	Washington University	Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5981215A (en)	1995-06-06	1999-11-09	Human Genome Sciences, Inc.	Human criptin growth factor
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
ATE234129T1 (de)	1996-06-18	2003-03-15	Alza Corp	Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
US6235724B1 (en)	1996-07-03	2001-05-22	Eisai Co., Ltd.	Injections containing lipid a analogues and process for the preparation thereof
US5955306A (en)	1996-09-17	1999-09-21	Millenium Pharmaceuticals, Inc.	Genes encoding proteins that interact with the tub protein
WO1998016247A1 (en)	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6231859B1 (en) *	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
KR100453132B1 (ko)	1996-12-20	2004-10-15	앨자 코포레이션	경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5840871A (en)	1997-01-29	1998-11-24	Incyte Pharmaceuticals, Inc.	Prostate-associated kallikrein
CA2281954A1 (en)	1997-02-25	1998-08-27	Corixa Corporation	Compounds for immunodiagnosis of prostate cancer and methods for their use
JP3036686B2 (ja)	1997-02-27	2000-04-24	政夫高橋	冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU743114B2 (en)	1997-04-01	2002-01-17	Corixa Corporation	Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
ZA982968B (en)	1997-04-09	1998-10-27	Corixa Corp	Compositions and methods for the treatment and diagnosis of breast cancer
WO1998050567A1 (en)	1997-05-02	1998-11-12	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
GB9711990D0 (en)	1997-06-11	1997-08-06	Smithkline Beecham Biolog	Vaccine
EP0988053A1 (de)	1997-06-11	2000-03-29	Aquila Biopharmaceuticals, Inc.	Gereinigte saponinen als orale adjuvantien
AU734180B2 (en)	1997-08-29	2001-06-07	Antigenics Llc	Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en)	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
EP1279401B1 (de)	1997-09-05	2008-01-09	GlaxoSmithKline Biologicals S.A.	Öl-in-Wasser Emulsionen mit Saponinen
WO1999019479A1 (en)	1997-09-26	1999-04-22	Corixa Corporation	Murine model for human carcinoma
CN1285753A (zh)	1997-12-02	2001-02-28	鲍德杰克特疫苗公司	透皮给药微粒疫苗组合物
CA2316397A1 (en)	1997-12-24	1999-07-08	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
BR9907691B1 (pt)	1998-02-05	2011-05-31		derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
JP2002511266A (ja)	1998-04-15	2002-04-16	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	腫瘍関連核酸及びその使用
DK1077722T3 (da) *	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
TR200100916T2 (de)	1998-07-14	2002-06-21	Corixa@@Corporation
ATE315405T1 (de) *	1998-08-10	2006-02-15	Antigenics Inc	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CN1133568C (zh)	1999-01-18	2004-01-07	地球制药株式会社	气溶胶扩散喷雾器
WO2000044899A1 (en)	1999-01-29	2000-08-03	Corixa Corporation	Her-2/neu fusion proteins
AU3391200A (en)	1999-03-04	2000-09-21	Corixa Corporation	Compositions and methods for breast cancer therapy and diagnosis
GB9905124D0 (en) *	1999-03-05	1999-04-28	Smithkline Beecham Biolog	Novel compounds
US6558670B1 (en) *	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
DK1187629T3 (da) *	1999-04-19	2005-01-17	Glaxosmithkline Biolog Sa	Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AU5788900A (en) *	1999-07-07	2001-01-22	Tularik Inc.	Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
SI1650221T1 (sl) *	2000-02-23	2012-09-28	Glaxosmithkline Biolog Sa	Nove spojine
AU2010252012A1 (en) *	2009-05-27	2011-12-22	Glaxosmithkline Biologicals S.A.	CASB7439 constructs

2001
- 2001-10-16 AT AT07121675T patent/ATE534401T1/de active
- 2001-10-16 PT PT01987671T patent/PT1326638E/pt unknown
- 2001-10-16 PL PL391896A patent/PL211151B1/pl unknown
- 2001-10-16 EP EP10170408A patent/EP2266603B1/de not_active Expired - Lifetime
- 2001-10-16 KR KR1020037005465A patent/KR100831139B1/ko not_active Expired - Fee Related
- 2001-10-16 ES ES10170408T patent/ES2392943T3/es not_active Expired - Lifetime
- 2001-10-16 DE DE60131670T patent/DE60131670T2/de not_active Expired - Lifetime
- 2001-10-16 DK DK07121675.8T patent/DK1889630T3/da active
- 2001-10-16 PT PT07121675T patent/PT1889630E/pt unknown
- 2001-10-16 DK DK10170408.8T patent/DK2266603T3/da active
- 2001-10-16 US US10/478,188 patent/US20050019340A1/en not_active Abandoned
- 2001-10-16 PT PT10170408T patent/PT2266603E/pt unknown
- 2001-10-16 ES ES07121675T patent/ES2377077T3/es not_active Expired - Lifetime
- 2001-10-16 SI SI200131015T patent/SI2266603T1/sl unknown
2003
- 2003-04-08 IL IL155282A patent/IL155282A/en not_active IP Right Cessation
2008
- 2008-01-31 CY CY20081100112T patent/CY1108526T1/el unknown
- 2008-05-14 JP JP2008126888A patent/JP2008285487A/ja active Pending
2012
- 2012-02-14 CY CY20121100147T patent/CY1112658T1/el unknown
- 2012-10-26 CY CY20121101024T patent/CY1113735T1/el unknown

Also Published As

Publication number	Publication date
CY1112658T1 (el)	2016-02-10
CY1113735T1 (el)	2016-06-22
KR20030044015A (ko)	2003-06-02
HK1117729A1 (en)	2009-01-23
ES2377077T3 (es)	2012-03-22
EP2266603B1 (de)	2012-09-12
PT1889630E (pt)	2012-02-29
EP2266603A1 (de)	2010-12-29
HK1147673A1 (en)	2011-08-19
SI2266603T1 (sl)	2012-12-31
PT2266603E (pt)	2012-11-02
CY1108526T1 (el)	2014-04-09
IL155282A (en)	2010-11-30
HK1057992A1 (en)	2004-04-30
PT1326638E (pt)	2008-02-06
DE60131670T2 (de)	2008-10-30
JP2008285487A (ja)	2008-11-27
US20050019340A1 (en)	2005-01-27
DE60131670D1 (de)	2008-01-10
KR100831139B1 (ko)	2008-05-20
DK1889630T3 (da)	2012-03-05
ES2392943T3 (es)	2012-12-17
PL211151B1 (pl)	2012-04-30
DK2266603T3 (da)	2012-11-05

Publication	Publication Date	Title
CY1113735T1 (el)	2016-06-22	Εμβολια ογκου
PT1104306E (pt)	2006-05-31	Composicoes de cpg e adjuvantes de saponina e seus metodos
DK1147117T3 (da)	2004-10-25	Immunologiske adjuvansforbindelser
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
ATE475668T1 (de)	2010-08-15	Immunisierung durch impfung von dns transkriptionseinheit
ATE406912T1 (de)	2008-09-15	Immunisierung gegen chlamydia tracheomatis
EP0705109A4 (de)	1998-09-02	Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
DE60037900D1 (de)	2008-03-13	Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
RU2006138283A (ru)	2008-06-10	Поливалентная вакцина для иммунотерапии рака на основе mage-3 и ny-eso-1
ATE370745T1 (de)	2007-09-15	Verbesserte polysaccharid- und glykokonjugat- vakzine
DK1140152T3 (da)	2003-12-01	Fremgangsmåde til fremstilling af inaktiverede v/o-emulsion-adjuvans-vacciner
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
AU2001284354A1 (en)	2002-02-13	Immunological adjuvant compounds, compositions, and methods of use thereof
DK0626008T3 (da)	2005-05-02	Vaccine, der som en adjuvans indeholder acemannan
WO1996012190A3 (en)	1996-06-27	Presentation of hydrophobic antigens to t-cells by cd1 molecules
WO2001015727A3 (en)	2001-09-07	Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
EA200800917A1 (ru)	2008-12-30	Адъюванты для вакцин
ATE374622T1 (de)	2007-10-15	Genetische impstoffe mit adjuvans
ATE345812T1 (de)	2006-12-15	Antigen-mimotope und vakzine gegen krebserkrankungen
DE69942161D1 (de)	2010-04-29	Genetische Adjuvanz-Impfstoffe